Lulu Hui

643 total citations
9 papers, 573 citations indexed

About

Lulu Hui is a scholar working on Molecular Biology, Cancer Research and Complementary and alternative medicine. According to data from OpenAlex, Lulu Hui has authored 9 papers receiving a total of 573 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 6 papers in Cancer Research and 3 papers in Complementary and alternative medicine. Recurrent topics in Lulu Hui's work include MicroRNA in disease regulation (6 papers), Natural Compounds in Disease Treatment (3 papers) and RNA modifications and cancer (2 papers). Lulu Hui is often cited by papers focused on MicroRNA in disease regulation (6 papers), Natural Compounds in Disease Treatment (3 papers) and RNA modifications and cancer (2 papers). Lulu Hui collaborates with scholars based in China and United States. Lulu Hui's co-authors include Wenlin Xu, Xiaolan Zhu, Huiling Shen, Lulu Long, Yuefeng Li, Hao Li, Hao Li, Hao Li, Hai‐Ning Chen and Xuefeng Wang and has published in prestigious journals such as Oncogene, FEBS Letters and Pharmaceutical Biology.

In The Last Decade

Lulu Hui

9 papers receiving 568 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lulu Hui China 8 450 397 76 31 30 9 573
Lulu Long China 8 401 0.9× 348 0.9× 59 0.8× 25 0.8× 30 1.0× 10 491
Keng Shen China 13 455 1.0× 309 0.8× 92 1.2× 49 1.6× 5 0.2× 40 602
Michael J. Bradaric United States 11 228 0.5× 119 0.3× 124 1.6× 46 1.5× 13 0.4× 16 488
Lei Lou China 13 274 0.6× 97 0.2× 80 1.1× 26 0.8× 7 0.2× 35 431
Xingnan Zheng United States 9 377 0.8× 184 0.5× 87 1.1× 24 0.8× 5 0.2× 12 477
Zhen Yuan China 11 175 0.4× 111 0.3× 58 0.8× 15 0.5× 6 0.2× 28 335
Sandipto Sarkar United States 13 242 0.5× 83 0.2× 114 1.5× 13 0.4× 12 0.4× 18 394
Paloma Silva de Souza Brazil 12 194 0.4× 63 0.2× 114 1.5× 23 0.7× 8 0.3× 15 333
Rosalba Rana Italy 10 312 0.7× 81 0.2× 102 1.3× 15 0.5× 10 0.3× 15 427
Mona El Khatib Germany 8 249 0.6× 135 0.3× 118 1.6× 36 1.2× 3 0.1× 9 418

Countries citing papers authored by Lulu Hui

Since Specialization
Citations

This map shows the geographic impact of Lulu Hui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lulu Hui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lulu Hui more than expected).

Fields of papers citing papers by Lulu Hui

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lulu Hui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lulu Hui. The network helps show where Lulu Hui may publish in the future.

Co-authorship network of co-authors of Lulu Hui

This figure shows the co-authorship network connecting the top 25 collaborators of Lulu Hui. A scholar is included among the top collaborators of Lulu Hui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lulu Hui. Lulu Hui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Zhu, Xiaolan, Huiling Shen, Xinming Yin, et al.. (2015). miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin. Oncogene. 35(3). 323–332. 137 indexed citations
2.
Hui, Lulu, et al.. (2015). A mathematical model of HTLV-I infection with two time delays. Mathematical Biosciences & Engineering. 12(3). 431–449. 26 indexed citations
3.
Zhu, Xiaolan, Yuefeng Li, Huiling Shen, et al.. (2012). miR‐137 inhibits the proliferation of lung cancer cells by targeting Cdc42 and Cdk6. FEBS Letters. 587(1). 73–81. 152 indexed citations
4.
Zhu, Xiaolan, Yuefeng Li, Huiling Shen, et al.. (2012). miR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1. Acta Biochimica et Biophysica Sinica. 45(2). 80–86. 48 indexed citations
5.
Li, Hao, Lulu Hui, Wenlin Xu, et al.. (2012). Triptolide modulates the sensitivity of K562/A02 cells to adriamycin by regulating miR-21 expression. Pharmaceutical Biology. 50(10). 1233–1240. 28 indexed citations
6.
Hui, Lulu, Wenlin Xu, Qiaoyun Chen, et al.. (2012). [Effect of triptolide on sensitivity of K562/A02 cell line to adriamycin].. PubMed. 20(1). 66–9. 1 indexed citations
7.
Li, Hao, Lulu Hui, & Wenlin Xu. (2012). miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2. Acta Biochimica et Biophysica Sinica. 44(3). 269–277. 53 indexed citations
8.
Zhu, Xiaolan, Hao Li, Lulu Long, et al.. (2012). miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A. Acta Biochimica et Biophysica Sinica. 44(6). 519–526. 105 indexed citations
9.
Li, Hao, Lulu Hui, Wenlin Xu, et al.. (2011). Modulation of P-glycoprotein expression by triptolide in adriamycin-resistant K562/A02 cells. Oncology Letters. 3(2). 485–489. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026